Literature DB >> 27534909

ABCB1-overexpressing MDCK-II cells are hypersensitive to 3-bromopyruvic acid.

Izabela Sadowska-Bartosz1, Jacek Grębowski2, Ewa Kępka2, Maciej Studzian2, Grzegorz Bartosz3, Łukasz Pułaski4.   

Abstract

AIMS: Cancer cells, due to the Warburg effect, are more dependent on glycolysis than normal cells, so glycolytic inhibitor 3-bromopyruvic acid (3-BP) was proposed as a promising candidate for anticancer therapy. Overexpression of multidrug transporters is the main reason of resistance of cancer cells to chemotherapy. As the activity of multidrug transporters imposes an energetic burden on the cells, it can be expected that inhibition of ATP generation may exert a selective cytotoxicity to cells overexpressing multidrug transporters. The aim of this study was to compare the effect of 3-BP on the survival and ATP level in MDCK-II cells and MDCK-II cells overexpressing ABCB1 (Pgp) or ABCG2 (BCRP). MAIN
METHODS: Cell survival was measured with resazurin and with neutral red. ATP level was assayed with luciferin/luciferase kit. Luteolin transport was measured by an original method described in the paper. KEY
FINDINGS: 3-BP (10-200μM) induced a decrease of ATP level after 1-h incubation in all cell lines studied, more drastically in ABCB1-overexpressing cells. 50 and 200μM 3-BP significantly decreased cell viability; the effect was more pronounced for ABCB1-overexpressing cells. PSC833, inhibitor of ABCB1, ameliorated the toxic effect of 3-BP on MDCK-II ABCB1 cells and MDCK-II cells. 3-BP inhibited luteolin transport in MDCK-II ABCG2 cells. SIGNIFICANCE: These results indicate that 3-BP shows selective toxicity against ABCB1- but not ABCG2-overexpressing cells, apparently due to enhanced ATP depletion but in a manner independent of the transport activity of Pgp, suggesting a novel mechanism of hypersensitivity of ABCB1-overexpressing cells to 3-BP.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3-Bromopyruvate; ABCB1 protein; ABCG2 protein; ATP; MDKC-II cells; Multidrug resistance

Mesh:

Substances:

Year:  2016        PMID: 27534909     DOI: 10.1016/j.lfs.2016.08.012

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells.

Authors:  Filipa Lopes-Coelho; Carolina Nunes; Sofia Gouveia-Fernandes; Rita Rosas; Fernanda Silva; Paula Gameiro; Tânia Carvalho; Maria Gomes da Silva; José Cabeçadas; Sérgio Dias; Luís G Gonçalves; Jacinta Serpa
Journal:  Oncotarget       Date:  2017-08-16

Review 2.  Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment.

Authors:  Tengjiao Fan; Guohui Sun; Xiaodong Sun; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

3.  Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3-Bromopyruvate.

Authors:  Natalia Pieńkowska; Grzegorz Bartosz; Paulina Furdak; Izabela Sadowska-Bartosz
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.